Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies

Immuno‐oncology therapies have the potential to revolutionize the armamentarium of available cancer treatments. To further improve clinical response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment. This Review highligh...

Descripción completa

Detalles Bibliográficos
Autores principales: Huck, Bayard R., Kötzner, Lisa, Urbahns, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900885/
https://www.ncbi.nlm.nih.gov/pubmed/28971564
http://dx.doi.org/10.1002/anie.201707816
_version_ 1783314499439165440
author Huck, Bayard R.
Kötzner, Lisa
Urbahns, Klaus
author_facet Huck, Bayard R.
Kötzner, Lisa
Urbahns, Klaus
author_sort Huck, Bayard R.
collection PubMed
description Immuno‐oncology therapies have the potential to revolutionize the armamentarium of available cancer treatments. To further improve clinical response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment. This Review highlights the significance of small molecules in this approach, which holds promise to provide increased benefit to cancer patients.
format Online
Article
Text
id pubmed-5900885
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59008852018-04-23 Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies Huck, Bayard R. Kötzner, Lisa Urbahns, Klaus Angew Chem Int Ed Engl Reviews Immuno‐oncology therapies have the potential to revolutionize the armamentarium of available cancer treatments. To further improve clinical response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment. This Review highlights the significance of small molecules in this approach, which holds promise to provide increased benefit to cancer patients. John Wiley and Sons Inc. 2018-02-22 2018-04-09 /pmc/articles/PMC5900885/ /pubmed/28971564 http://dx.doi.org/10.1002/anie.201707816 Text en © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Huck, Bayard R.
Kötzner, Lisa
Urbahns, Klaus
Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
title Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
title_full Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
title_fullStr Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
title_full_unstemmed Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
title_short Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
title_sort small molecules drive big improvements in immuno‐oncology therapies
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900885/
https://www.ncbi.nlm.nih.gov/pubmed/28971564
http://dx.doi.org/10.1002/anie.201707816
work_keys_str_mv AT huckbayardr smallmoleculesdrivebigimprovementsinimmunooncologytherapies
AT kotznerlisa smallmoleculesdrivebigimprovementsinimmunooncologytherapies
AT urbahnsklaus smallmoleculesdrivebigimprovementsinimmunooncologytherapies

Ejemplares similares